Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 724.

https://doi.org/10.1182/blood.V130.Suppl_1.724.724

Published: 2017

Journal Articles

Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study

Blood (2017) 130 (Supplement 1): 725.

https://doi.org/10.1182/blood.V130.Suppl_1.725.725

Published: 2017

Journal Articles

Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1

Blood (2016) 128 (22): 1070.

https://doi.org/10.1182/blood.V128.22.1070.1070

Published: 2016

Journal Articles

Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study

Courtney DiNardo, MD, Stéphane de Botton, Daniel A Pollyea, Eytan M Stein, Amir T. Fathi, MD, Gail J Roboz, MD, Robert Collins, MD, Ronan T. Swords, MDPhDFRCPI FRCPath, Ian W. Flinn, MD PhD, Jessica K Altman, Martin S Tallman, MD, Hagop M. Kantarjian, MD, Adnan Derti, Meredith Goldwasser, Malia Prahl, Bin Wu, Katharine Yen, Sam Agresta, Richard M. Stone, MD

Blood (2015) 126 (23): 1306.

https://doi.org/10.1182/blood.V126.23.1306.1306

Published: 2015

Journal Articles

IDH1 Splicing Alterations in Patients with AML and Their Relationship to Blood 2HG Levels

Sophia Adamia, PhD, Patricia Toniolo, PhDcandidate, Amir T. Fathi, MD, Ilene Galinsky, ANP, Suiyang Liu, Katharine Yen, Hyeryun Kim Kim, Dongwei Zhu, Straley Kim, Martha Wadleigh, MD, David P. Steensma, MD, Ibiayi Dagogo-Jack, MD, Daniel J. DeAngelo, MD PhD, James D. Griffin, MD, Richard M. Stone, MD

Blood (2014) 124 (21): 1060.

https://doi.org/10.1182/blood.V124.21.1060.1060

Published: 2014

Journal Articles

AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies

Blood (2014) 124 (21): 115.

https://doi.org/10.1182/blood.V124.21.115.115

Published: 2014

Journal Articles

Diagnostic Features and 2-Hydroxyglutarate (2-HG) Levels Among Acute Myeloid Leukemia (AML) Patients with and without Isocitrate Dehydrogenase (IDH) Mutations

Blood (2014) 124 (21): 1045.

https://doi.org/10.1182/blood.V124.21.1045.1045

Published: 2014

Journal Articles

AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo

Erica Hansen, Cyril Quivoron, Kim Straley, René M Lemieux, Janeta Popovici-Muller, Hossein Sadrzadeh, Amir T Fathi, Camelia Gliser, Muriel David, Véronique Saada, Jean-Baptiste Micol, Olivier Bernard, Marion Dorsch, Hua Yang, Michael Su, Sam Agresta, Stéphane de Botton, Virginie Penard-Lacronique, Katharine Yen

Blood (2014) 124 (21): 3734.

https://doi.org/10.1182/blood.V124.21.3734.3734

Published: 2014

Journal Articles

AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model

Cyril Quivoron, Muriel David, Kim Straley, Jeremy Travins, Hyeryun Kim, Yue Chen, Dongwei Zhu, Véronique Saada, Olivia Bawa, Paule Opolon, Mélanie Polrot, Jean-Baptiste Micol, Christophe Willekens, Olivier Bernard, Hua Yang, Sam Agresta, Stéphane de Botton, Katharine Yen, Virginie Penard-Lacronique

Blood (2014) 124 (21): 3735.

https://doi.org/10.1182/blood.V124.21.3735.3735

Published: 2014

Journal Articles

Evaluation of Pharmacokinetic-Pharmacodynamic (PKPD) Relationship of an Oral, Selective, First-in-Class, Potent IDH2 Inhibitor, AG-221, from a Phase 1 Trial in Patients with Advanced IDH2 Mutant Positive Hematologic Malignancies

Bin Fan, Yue Chen, Fang Wang, Katharine Yen, Luke Utley, Caroline Almon, Scott Biller, Sam Agresta, Hua Yang

Blood (2014) 124 (21): 3737.

https://doi.org/10.1182/blood.V124.21.3737.3737

Published: 2014

Journal Articles

IDH1 Mutant Inhibitor Induces Cellular Differentiation and Offers a Combination Benefit With Ara-C In a Primary Human Idh1 Mutant AML Xenograft Model

Katharine Yen, Ph.D., Rene Lemieux, Ph.D., Janeta Popovici-Muller, Yue Chen, Ph.D., Hua Yang, Kim Straley, Sung Choe, Marion Dorsch, Samuel Agresta, MD, David P. Schenkein, MD, Scott Biller, Michael Su, Fang Wang

Blood (2013) 122 (21): 3946.

https://doi.org/10.1182/blood.V122.21.3946.3946

Published: 2013

Journal Articles

AG-221 Offers a Survival Advantage In a Primary Human IDH2 Mutant AML Xenograft Model

Katharine Yen, Ph.D., Fang Wang, Jeremy Travins, Yue Chen, Ph.D., Hua Yang, Kim Straley, Sung Choe, Marion Dorsch, David P. Schenkein, MD, Samuel Agresta, MD, Scott Biller, Michael Su

Blood (2013) 122 (21): 240.

https://doi.org/10.1182/blood.V122.21.240.240

Published: 2013

Journal Articles

Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia

Blood (2013) 121 (24): 4917–4924.

https://doi.org/10.1182/blood-2013-03-493197

Published: 2013

Includes: Supplemental data

Journal Articles

Mutation Selective IDH Inhibitors Mediate Histone and DNA Methylation Changes

Blood (2012) 120 (21): 3509.

https://doi.org/10.1182/blood.V120.21.3509.3509

Published: 2012

Journal Articles

Serum 2-Hydroxyglutarate Levels Predict Isocitrate Dehydrogenase Mutations and Clinical Outcome in Acute Myeloid Leukemia.

Courtney D. DiNardo, MD, Ross L. Levine, Kathleen J Propert, ScD, Alison W. Loren, MD, Elisabeth Paietta, PhD, Zhouxin Sun, PhD, Kimberly Straley, BS, Katharine Yen, Jay P. Patel, Samuel Agresta, MD, Omar Abdel-Wahab, Alexander E Perl, MD, Hugo F Fernandez, MD, David Margolis, MD, MSCE, Martin S. Tallman, MD, Selina M. Luger, MD, Martin Carroll, MD

Blood (2012) 120 (21): 2481.

https://doi.org/10.1182/blood.V120.21.2481.2481

Published: 2012

NARROW

Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia

Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study

Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1

Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study

IDH1 Splicing Alterations in Patients with AML and Their Relationship to Blood 2HG Levels

AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies

Diagnostic Features and 2-Hydroxyglutarate (2-HG) Levels Among Acute Myeloid Leukemia (AML) Patients with and without Isocitrate Dehydrogenase (IDH) Mutations

AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo

AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model

Evaluation of Pharmacokinetic-Pharmacodynamic (PKPD) Relationship of an Oral, Selective, First-in-Class, Potent IDH2 Inhibitor, AG-221, from a Phase 1 Trial in Patients with Advanced IDH2 Mutant Positive Hematologic Malignancies

IDH1 Mutant Inhibitor Induces Cellular Differentiation and Offers a Combination Benefit With Ara-C In a Primary Human Idh1 Mutant AML Xenograft Model

AG-221 Offers a Survival Advantage In a Primary Human IDH2 Mutant AML Xenograft Model

Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia

Mutation Selective IDH Inhibitors Mediate Histone and DNA Methylation Changes

Serum 2-Hydroxyglutarate Levels Predict Isocitrate Dehydrogenase Mutations and Clinical Outcome in Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only